Cleared Traditional

K214004 - CCBIO ASCPO Needle

K214004 is an FDA 510(k) clearance for CCBIO ASCPO Needle, manufactured by Cc Biotechnology Corporation. The device is a Class 2 General Hospital device with product code FMI cleared through the Traditional 510(k) pathway after a 357-day FDA review.

K214004 · Cc Biotechnology Corporation · General Hospital
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2022
Decision
357d
Days
Class 2
Risk

K214004 is an FDA 510(k) clearance for the CCBIO ASCPO Needle. Classified as Needle, Hypodermic, Single Lumen (product code FMI), Class II - Special Controls.

Submitted by Cc Biotechnology Corporation (Tainan, TW). The FDA issued a Cleared decision on December 13, 2022 after a review of 357 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the General Hospital FDA review panel, regulated under 21 CFR 880.5570 - the FDA general hospital device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the General Hospital review framework, consistent with the majority of Class II 510(k) submissions.

View all Cc Biotechnology Corporation devices

FDA 510(k) Submission Details - K214004

510(k) Number K214004 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received December 21, 2021
Decision Date December 13, 2022
Days to Decision 357 days
Submission Type Traditional
Review Panel General Hospital (HO)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
228d slower than avg
Panel avg: 129d · This submission: 357d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

FMI Device Classification - Class 2, Special Controls

Product Code FMI Needle, Hypodermic, Single Lumen
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 880.5570
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most General Hospital devices follow this clearance model.

Regulatory Peers - FMI Needle, Hypodermic, Single Lumen

All 271
Devices cleared under the same product code (FMI) and FDA review panel - the closest regulatory comparables to K214004.
Insupen Pen needle, Insupen ORIGINAL Pen Needle, Insupen ADVANCED pen needle
K203792 · Pikdare Spa · Jan 2023
BD AutoShield Duo™ Pen Needle
K223286 · Becton, Dickinson and Company · Dec 2022
Sterile Hypodermic Needles for Single Use
K223334 · Zhejiang Kindly Medical Devices Co., Ltd. · Dec 2022
Altaviz Needle Kit
K222681 · Altaviz, LLC · Dec 2022
DropSafeTM SicuraTM
K223353 · Pikdare Spa · Dec 2022
Disposable Insulin Pen Needle
K221178 · Ningbo Medsun Medical Co., Ltd. · Nov 2022